Literature DB >> 1676357

Pharmacokinetics of esmolol in children.

D B Wiest1, D L Trippel, P C Gillette, S S Garner.   

Abstract

The pharmacokinetics and concentration-response relationships of intravenous esmolol were investigated in 20 children undergoing indicated cardiac electrophysiologic testing. A loading dose of 600 micrograms/kg was infused for 2 minutes. An infusion of esmolol was initiated and dosage was titrated until beta-blockade occurred. Serial esmolol blood samples were obtained for pharmacokinetic analysis. Non-compartmental pharmacokinetic analysis of the data revealed the following parameter estimates (mean +/- SD): volume of distribution at steady state, 2.0 +/- 1.4 L/kg; total body clearance, 321.2 +/- 238.8 ml/kg/min; and terminal elimination half-life, 4.5 +/- 2.1 minutes. There was a significant correlation between mean esmolol concentrations and mean percentage of reductions of mean arterial pressures and heart rates at each sample time (p less than 0.001). The doses of esmolol required for beta-blockade (mean +/- SD, 535 +/- 180 micrograms/kg/min) in children were considerably higher than those typically used in adults. Esmolol should prove useful in children in the acute management of cardiac arrhythmias and hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676357     DOI: 10.1038/clpt.1991.78

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias.

Authors:  Peter C Adamson; Larry A Rhodes; J Philip Saul; MacDonald Dick; Michael R Epstein; Peter Moate; Raymond Boston; Mark S Schreiner
Journal:  Pediatr Cardiol       Date:  2006-07-11       Impact factor: 1.655

Review 3.  Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.

Authors:  D Wiest
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

4.  Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Authors:  Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

5.  Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.

Authors:  B F Cuneo; V R Zales; P C Blahunka; D W Benson
Journal:  Pediatr Cardiol       Date:  1994 Nov-Dec       Impact factor: 1.655

6.  Successful treatment of long QT syndrome-induced ventricular tachycardia with esmolol.

Authors:  J Balcells; M Rodríguez; M Pujol; J Iglesias
Journal:  Pediatr Cardiol       Date:  2004 Mar-Apr       Impact factor: 1.655

7.  Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies.

Authors:  Atsuko Ashida; Noriyasu Ozaki; Kanta Kishi; Yutaka Odanaka; Shintaro Nemoto; Hayato Konishi; Akira Ashida
Journal:  Pediatr Cardiol       Date:  2021-06-07       Impact factor: 1.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.